Navigation Links
MD Anderson study finds increases in 5-, 10-year survival at every stage of breast cancer
Date:9/29/2010

HOUSTON - Advances in screening for disease detection, better surgical techniques available to more women, and an increased number of therapies that reduce the risk of relapse in patients with both locally advanced and early stage disease, have collectively contributed to dramatic improvements in breast cancer's survival rates, according to a review of 60 years of patient records at The University of Texas MD Anderson Cancer Center.

The single institution study found increases in both five and 10-year survival at every stage of the disease in every decade studied. Aman Buzdar, M.D., professor in MD Anderson's Department of Breast Medical Oncology presented the data in advance of the 2010 Breast Cancer Symposium.

Similar to that of the National Cancer Institute's (NCI) Surveillance, Epidemiology and End Results Program (SEER), MD Anderson's Department of Breast Medical Oncology has maintained a comprehensive database collecting information on incidence, prevalence and mortality since the institution's inception almost 70 years ago. MD Anderson is in a unique position in that it has the largest group in the country, perhaps in the world, committed to the treatment of breast cancer, explains Buzdar.

"The concept of combined, multi-disciplinary approach for the management of breast cancer care, and that of other cancers, was introduced early on and remains the cornerstone of our care," says Buzdar, the study's senior author. "At MD Anderson, new therapeutic advances have long-been incorporated into the clinical care of patients early-on, resulting in improved survival of patients within each stage of disease. Over the years, with the discovery of research milestones, we have published studies looking at MD Anderson patients to determine how these discoveries have impacted their survival."

For this retrospective, single-institution study, Buzdar and his team reviewed records of 56,864 breast cancer patients seen at MD Anderson between 1944 and 2004. Of those, 12,809 women had their initial therapy at the institution. For each decade, patients were determined to have one of three stages of disease: local, regional and distant, or metastatic.

Across the decades, the researchers looked at five and 10-year survival by stage, both of which were calculated from the date of initial presentation. From decade to decade, the researchers found an impressive increase in survival in all three stages of the disease, as well as overall survival:

Years Percent survival at 10 years (number of patients)
Local Disease Regional Disease Distant Disease Overall*
1944-54 55.0% (120) 16.2% (191) 3.3% (92) 25.1% (410)
1955-64 56.0% (462) 23.9% (656) 4.0% (306) 30.5% (1,449)
1965-74 59.3% (440) 28.8% (566) 4.7% (321) 34.6% (1,387)
1975-84 72.0% (701) 46.9% (828) 7.4% (367) 49.3% (1,983)
1985-94 78.5% (1,036) 57.4% (1,268) 11.2% (364) 61.6% (2,927)
1995-04 86.1% (1,898) 74.1% (1,569) 22.2% (455) 76.5% (4,653)
*Also includes patients with in situ or unknown stages of the disease

Buzdar notes the improved survival in metastatic patients of great significance as these patients have disease that may not be curable, yet a significant proportion of these patients can now live for a number of years with available therapies.

"In the first decade we tracked, 1944-1954, the 10-year survival of women with metastatic breast cancer was just 3.3 percent. However, between the decades of 1985-1994 and 1995-2004, the survival gain in the same cohort increased from 11.2 to 22.2 percent, respectively. This dramatic shift is a true testament to not only breast cancer's overall research and clinical milestones - improved chemotherapies, addition of new drugs, improvement of endocrine therapies and more recently biologics - but to the appropriate and disciplined approach and utilization of these therapies," says Buzdar.

A number of MD Anderson's research milestones have impacted clinical care and breast cancer survival, both at the institution, and beyond, says Buzdar, including: combined modality approach to the treatment of the disease; utilization of systemic therapies prior to surgery; refinement of chemotherapies, specifically the incorporation of anthracyclines, taxanes and biologics, and newer hormonal agents like aromatase inhibitors.

While these research milestones and study findings are obviously encouraging, still more needs to be done, he says.

"Now, we need to turn our attention to the refinement of breast cancer therapies, with a goal of further decreasing risk of recurrence and death for our high-risk early stage breast cancer patients, and maintaining the control of disease in those with metastatic disease," says Buzdar.


'/>"/>

Contact: Laura Sussman
lsussman@mdanderson.org
713-745-2457
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert

Related medicine news :

1. David Anderson to discuss what model organisms can teach us about emotion
2. LodgeNet Healthcare Deploys Custom Education Solution for M. D. Anderson Cancer Center
3. M. D. Anderson develops tool to measure severity of chronic graft-vs.-host disease symptoms
4. Costly tests may not help detect bladder cancer recurrence, M. D. Anderson study finds
5. M. D. Anderson zeroes in on better way to predict prognosis in pediatric leukemia patients
6. M. D. Anderson receives 4.5 million grant, largest ever for study of yoga and cancer
7. NACDS' Anderson Says Retailers and Suppliers' “Health and Wellness Renaissance” is Creating a “Historic, Watershed Moment”
8. Anderson & Kriger Takes Donations to Families Affected by Baja's Easter Earthquake
9. Peg Fields to receive MD Andersons highest nurse-oncologist honor
10. MD Anderson keeps No. 1 cancer ranking in US News & World Report annual survey
11. UT MD Anderson study finds women treated for breast cancer while pregnant have improved survival
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... Battle Creek, MI (PRWEB) , ... January 17, 2017 , ... ... substance abuse located in Southwest Michigan, joined other volunteers and organizations in support of ... sees hundreds of children and families dressed up in colorful costumes of all designs ...
(Date:1/16/2017)... ... January 16, 2017 , ... ... their groundbreaking GunSport•PRO® and EB15•LE® electronic earplugs at the NSSF SHOT Show on ... Booth #2809. The SHOT Show is the shooting, hunting and outdoor trade show ...
(Date:1/16/2017)... , ... January 16, 2017 , ... ... , Antoine Dental Center, is currently offering complimentary consultations and financing for orthodontics ... teeth examined for bite irregularities and learn about their orthodontic options. Walk-in, late-evening, ...
(Date:1/16/2017)... ... 2017 , ... Specialty Technical Publishers (STP) and Specialty Technical ... (IAPC) EHS audit protocol for Singapore . Leading companies around the world ... obligations and rapidly collect, share, archive, and export audit findings in a cost ...
(Date:1/16/2017)... ... January 16, 2017 , ... ... science teacher, http://www.ageofautism.com/legal , Sharon Kleyne, America’s leading water educator, researcher ... her nationally syndicated radio program, The Sharon Kleyne Hour Power of Water, Global ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... BAUDETTE, Minn. , Jan. 17, 2017 /PRNewswire/ ... ) today announced the appointment of Karen Quinn ... January 17, 2017.  Karen ... years of leadership experience in Global Regulatory Affairs, ... biologically-derived active pharmaceutical ingredients.  Dr. Quinn worked most ...
(Date:1/17/2017)... pioneer in no-touch UV disinfection has now been validated by ... for "total room ultraviolet disinfection," was the device of choice ... study which was recently published in The Lancet ... transmission of four major superbugs by a cumulative 30 percent. ... we have been committed to innovation and the science behind ...
(Date:1/16/2017)... Research and Markets has announced the addition ... to their offering. ... Global multiple myeloma drugs market to grow at a CAGR ... covers the present scenario and the growth prospects of the global ... the report considers the revenue generated from the sales of branded ...
Breaking Medicine Technology: